# Crosstalk Between the Oncoproteins of High‐Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models

## TL;DR

This study shows that combining HPV 16 and 18 oncoproteins increases cancer growth and spread in colorectal cancer cells, especially in TP53 mutant cells.

## Contribution

The study reveals a synergistic effect of HPV 16 and 18 E6/E7 oncoproteins in enhancing CRC oncogenesis.

## Key findings

- Co-expression of HPV 16 and 18 E6/E7 oncoproteins increased cell proliferation, invasion, migration, and survival in CRC models.
- Deregulation of EMT biomarkers E-cadherin, fascin, and vimentin was observed in co-transfected cells.
- HPV 18 induced a stronger and more sustained oncogenic effect compared to HPV 16, particularly in TP53 mutant cells.

## Abstract

Colorectal cancer (CRC) represents a major fraction of the total cancer burden worldwide. It has been recently identified that various high‐risk Human Papillomaviruses (HPVs) are present in human CRCs, where they play a critical role in the development and progression of the cancer.

In this study, we explored the synergistic effect of the E6/E7 viral oncoproteins of the two most frequently observed HPV types (16 and 18) on KRAS and TP53 mutant CRC cell models.

We performed an experimental in vitro study utilizing lipofection to transfect KRAS and TP53 mutant CRC cell models (HCT 116 and HT‐29 respectively) with E6/E7 oncoproteins of HPV types 16 and 18 individually and in combination. Subsequently, we assessed their synergistic effect on cell proliferation, invasion, migration, and survival. In addition, we also compared the protein expression patterns of key epithelial‐mesenchymal transition (EMT) biomarkers like E‐cadherin, fascin, and vimentin among transfected, co‐transfected, and wild‐type cells.

We found that the co‐expression of E6/E7 of HPV types 16 and 18 enhanced cell proliferation, invasion, migration, and survival in both cell models. Interestingly, this was also accompanied by the deregulation of all three EMT biomarkers, E‐cadherin, fascin, and vimentin. The synergistic effect of the viral oncoproteins in promoting cancer was more pronounced in TP53 mutant cells (HT‐29) as compared to KRAS mutant cells (HCT 116). We also report that HPV type 18 can induce a greater and more sustained oncogenic outcome as compared to HPV type 16.

Our data indicate that co‐expression of the E6/E7 oncoproteins of HPV types 16 and 18 can enhance oncogenic processes in CRC, especially TP53 mutant CRC.